Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biotechnology company based in South San Francisco, developing innovative treatments for major metabolic diseases, including non-alcoholic steatohepatitis (NASH). Focused on creating best-in-class medicines, Akero's lead clinical program centers on efruxifermin (EFX), a modified FGF21 protein designed to reduce liver fat, inflammation, and fibrosis. EFX is engineered to target both the liver and adipose tissue, offering potential comprehensive benefits to NASH patients.
Building on over two decades of FGF21 research, Akero has achieved significant milestones. Their Phase 2b HARMONY study, evaluating EFX in pre-cirrhotic NASH patients, demonstrated impressive results at Week 96, including substantial fibrosis improvement and liver health biomarkers. Additionally, the SYNCHRONY program encompasses multiple Phase 3 clinical trials aimed at both cirrhotic and pre-cirrhotic NASH patients, further validating the efficacy and safety profile of EFX.
Akero's rigorous clinical trials and outstanding engagement with the FDA underscore their commitment to addressing high unmet medical needs. Their recent public stock offering has bolstered financial stability, ensuring sustained progress in their groundbreaking research and development efforts. For more information, visit Akero Therapeutics and follow them on LinkedIn and Twitter.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Jefferies Global Healthcare Conference on June 9, 2022, at 4:00 p.m. E.T. This clinical-stage company focuses on innovative treatments for serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. Their lead candidate, efruxifermin (EFX), is designed for convenient weekly subcutaneous dosing and is under evaluation in two Phase 2b clinical trials. The presentation will be webcasted live, with archived replays available on their website.
Akero Therapeutics (Nasdaq: AKRO) is progressing well in its clinical trials for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). The company reported Q1 2022 financial results, with cash reserves of $165.4 million expected to sustain operations into Q3 2023. Research and development expenses surged to $20.5 million, reflecting ongoing clinical trials. Total operating expenses reached $26.1 million, compared to $15.1 million in Q1 2021. Akero anticipates reporting results from its Phase 2b HARMONY study in Q3 2022.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference includes a fireside chat on May 11 at 8:40 a.m. PT in Las Vegas, while the H.C. Wainwright Annual Global Life Sciences Conference offers on-demand viewing of a fireside chat on May 24 at 7:00 a.m. ET. Webcasts will be accessible on their website, with archived replays available later. Akero is focused on developing innovative treatments for serious metabolic diseases, particularly NASH.
Akero Therapeutics (Nasdaq: AKRO) reported its financial results for the fourth quarter and full year 2021, indicating cash reserves of $188.3 million, sufficient to fund operations into Q3 2023. The company is on track to release results from the Phase 2b HARMONY study for its lead candidate, efruxifermin (EFX), in Q3 2022. Increased R&D expenses of $81.8 million for 2021 are attributed to the EFX program. Akero has made advancements in manufacturing capabilities, including a new drug formulation in a dual-chamber syringe device for self-administration.
Akero Therapeutics (Nasdaq: AKRO) has completed enrollment in its Phase 2b HARMONY study for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). This follows promising Phase 2a results where 48% of patients showed fibrosis improvement after 16 weeks. The Phase 2b trial involves a longer 24-week treatment period, aiming for fibrosis regression. Preliminary results are expected in Q3 2022. EFX is designed for convenient dosing and may become a leading NASH treatment if proven effective.
Akero Therapeutics (Nasdaq: AKRO) announced its participation at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. E.T. The live presentation will be accessible via the investor relations section of their website, with archived replays available afterward.
Akero is focused on developing therapies for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, efruxifermin (EFX), is undergoing Phase 2b trials and aims to provide a groundbreaking treatment option for patients.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2 at 3:30 p.m. E.T. This event will include a management fireside chat, which will be accessible via a live webcast on the company's investor relations page. Akero Therapeutics focuses on developing treatments for serious metabolic diseases, specifically targeting non-alcoholic steatohepatitis (NASH). Its lead candidate, efruxifermin (EFX), is currently undergoing two Phase 2b trials aimed at assessing its effectiveness in various patient groups.
On November 12, 2021, Akero Therapeutics (Nasdaq: AKRO) reported promising results from a post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH). After 16 weeks, 87% (35 of 40) of EFX-treated patients showed improvements in steatohepatitis, while 80% (32 of 40) demonstrated fibrosis improvement. The findings were presented at The Liver Meeting of the American Association for the Study of Liver Diseases. Akero is optimistic about the upcoming Phase 2b studies and the potential for EFX to become a leading treatment for NASH.
Akero Therapeutics (AKRO) reported its Q3 2021 financial results, highlighting a cash position of $215.1 million, sufficient to fund operations into Q3 2023. The company is progressing in two Phase 2b clinical trials for efruxifermin (EFX) targeting non-alcoholic steatohepatitis (NASH). Notably, the FDA granted Fast Track designation for EFX, enabling more frequent interactions and potential priority review. Q3 research and development expenses increased to $19.5 million, with total operating expenses at $24.4 million, compared to $21.5 million in Q3 2020.
Akero Therapeutics (Nasdaq: AKRO) announced participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing on November 18 at 3:00 a.m. EST. Known for its focus on serious metabolic diseases, Akero is developing efruxifermin (EFX), a potential best-in-class treatment for non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. EFX is undergoing evaluation in two Phase 2b trials: HARMONY and SYMMETRY.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
What is Akero Therapeutics' main focus?
What is efruxifermin (EFX)?
What are the key results from the HARMONY study?
What is the SYNCHRONY program?
How is Akero Therapeutics funded for their research?
What is the significance of Akero's work with the FDA?
Where is Akero Therapeutics headquartered?
How can I get more information about Akero Therapeutics?
